ReviewBlood2018
Chimeric antigen receptor-modified T cells: CD19 and the road beyond.
Review in Blood, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 99 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
99 citing papers in PubMed, 1 synthesis or guideline pooled it, 164 citations in OpenAlex.
- Cardiovascular effects associated with chimeric antigen receptor T cell therapy in cancer patients: A meta-analysis.Frontiers in oncology · 2022Pooled it
- Decitabine and Vorinostat with Chemotherapy in Relapsed Pediatric Acute Lymphoblastic Leukemia: A TACL Pilot Study.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020Trial
- Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study.Journal of hematology & oncology · 2020Trial
- Predicting hepatic complications of allogeneic hematopoietic stem cell transplantation using liver stiffness measurement.Bone marrow transplantation · 2019Trial
- A phase 2 study of alpha interferon for molecularly measurable residual disease in chronic myeloid leukemia after allogeneic hematopoietic cell transplantation.Leukemia & lymphoma · 2019Trial
- T-Cell Receptor Gene Therapy for Human Papillomavirus-Associated Epithelial Cancers: A First-in-Human, Phase I/II Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019Trial
- Microfluidic-based rapid generation of chimeric antigen receptor T cells improves low-multiplicity-of-infection transduction efficiency while preserving functional activity.Journal of translational medicine · 2026Article
- Cell Cycle Sensing Shapes Human T Cell Fate and Exhaustion Programs.bioRxiv : the preprint server for biology · 2026Article
- Impact of Glycine-Serine Linker on Target Antigen Binding and Subsequent CD37CAR-T Performance.International journal of molecular sciences · 2026Article
- Review
- Advancing Cancer Immunotherapy: Chimeric Antigen Receptor (CAR)-T Cell Engineering through Novel Screening Methods.Biomolecules & therapeutics · 2026Review
- Comparative Preclinical Analysis of Anti-B7-H3 CAR-T Cells Targeting Neuroblastoma.Biomedicines · 2025Article
- Cardiovascular adverse effects of immunotherapy in cancer: insights and implications.Frontiers in oncology · 2025Review
- Frontiers of cytokine engineering in CAR cell therapy for cancer.Frontiers in oncology · 2025Review
- CAR-T Cell Therapy: Managing Side Effects and Overcoming Challenges.Advanced biomedical research · 2025Review
- Generation ofHeliyon · 2024Article
- Co-stimulation of CD28/CD40 signaling molecule potentiates CAR-T cell efficacy and stemness.Molecular therapy. Oncology · 2024Article
- Immune modulatory microRNAs in tumors, their clinical relevance in diagnosis and therapy.Journal for immunotherapy of cancer · 2024Review
- Targeting autophagy overcomes cancer-intrinsic resistance to CAR-T immunotherapy in B-cell malignancies.Cancer communications (London, England) · 2024Article
- Breakthrough in Blastic Plasmacytoid Dendritic Cell Neoplasm Cancer Therapy Owing to Precision Targeting of CD123.International journal of molecular sciences · 2024Review
39 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
The ability to harness a patient's immune system to target malignant cells is now transforming the treatment of many cancers, including hematologic malignancies. The adoptive transfer of T cells selected for tumor reactivity or engineered with natural or synthetic receptors has emerged as an effective modality, even for patients with tumors that are refractory to conventional therapies. The most notable example of adoptive cell therapy is with T cells engineered to express synthetic chimeric antigen receptors (CARs) that reprogram their specificity to target CD19. CAR T cells have shown remarkable antitumor activity in patients with refractory B-cell malignancies. Ongoing research is focused on understanding the mechanisms of incomplete tumor elimination, reducing toxicities, preventing antigen escape, and identifying suitable targets and strategies based on established and emerging principles of synthetic biology for extending this approach to other hematologic malignancies. This review will discuss the current status, challenges, and potential future applications of CAR T-cell therapy in hematologic malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.